CoChat

Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice

Open access
Ma, Jing, Gao, Yuan, Jiang, Lin, Chao, Feng-lei, Huang, Wei, Zhou, Chun-ni, Tang, Wei, Zhang, Lei, Huang, Chun-xia, Zhang, Yi, Luo, Yan-min, Xiao, Qian, Yu, Hua-rong, Jiang, Rong, Tang, Yong · 2017 · Oncotarget
Cited by 51

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

// Jing Ma 1,2 , Yuan Gao 3 , Lin Jiang 1,2 , Feng-lei Chao 1,2 , Wei Huang 1,2 , Chun-ni Zhou 1,2 , Wei Tang 1,2 , Lei Zhang 1,2 , Chun-xia Huang 4 , Yi Zhang 1,2 , Yan-min Luo 1,2 , Qian Xiao 1,2 , Hua-rong Yu 4 , Rong Jiang 1,2 and Yong Tang 1,2 1 Department of Histology and Embryology, Chongqing Medical University, Chongqing, P. R. China 2 Laboratory of Stem Cells and Tissue Engineering, Chongqing Medical University, Chongqing, P. R. China 3 Department of Geriatrics, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P. R. China 4 Department of Physiology, Chongqing Medical University, Chongqing, P. R. China Correspondence to: Yong Tang, email: // Keywords : fluoxetine, Alzheimer’s disease, cognition, neuron, APP/PS1 mice, Gerotarget Received : July 04, 2016 Accepted : January 31, 2017 Published : February 16, 2017 Abstract Selective serotonin reuptake inhibitors (SSRIs) have been reported to increase cognitive performance in some clinical studies of Alzheimer’s disease (AD). However, there is a lack of evidence supporting the efficacy of SSRIs as cognition enhancers in AD, and the role of SSRIs as a treatment for AD remains largely unclear. Here, we characterized the impact of fluoxetine (FLX), a well-known SSRI, on neurons in the dentate gyrus (DG) and in CA1 and CA3 of the hippocampus of middle-aged (16 to 17 months old) APPswe/PSEN1dE9 (APP/PS1) transgenic AD model mice. We found that intraperitoneal (i.p.) injection of FLX (10 mg/kg/day) for 5 weeks effectively alleviated the impairment of spatial learning ability in middle-aged APP/PS1 mice as evaluated using the Morris water maze. More importantly, the number of neurons in the hippocampal DG was significantly increased by FLX. Additionally, FLX reduced the deposition of beta amyloid, inhibited GSK-3β activity and increased the level of β-catenin in middle-aged APP/PS1 mice. Collectively, the results of this study indicate that FLX delayed the progression of neuronal loss in the hippocampal DG in middle-aged AD mice, and this effect may underlie the FLX-induced improvement in learning ability. FLX may therefore serve as a promising therapeutic drug for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15398

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 51

Metadata

Authors
Ma, J., Gao, Y., Jiang, L., Chao, F.-L., Huang, W., Zhou, C.-N., Tang, W., Zhang, L., Huang, C.-X., Zhang, Y., Luo, Y.-M., Xiao, Q., Yu, H.-R., Jiang, R., & Tang, Y.
Venue
Oncotarget
Published
2017-02-16
Volume
8
Issue
17
Pages
27676-27692
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2590078180
Cited by
51
References
31
FWCI
3.43
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.